An Open-Label, Three Period, Fixed Sequence Study to Assess the Effect of a Single Dose of BIA 5 1058 200 mg on the Steady State Pharmacokinetics of Treprostinil in Healthy Subjects Under Fed Conditions
Latest Information Update: 26 Jun 2021
At a glance
- Drugs Treprostinil (Primary) ; Zamicastat (Primary)
- Indications Pulmonary arterial hypertension
- Focus Pharmacokinetics
- Sponsors BIAL - Portela C S.A.
- 19 May 2021 Results assessing the effect of single dose of zamicastat on the steady-state pharmacokinetics of treprostinil and the effect of treprostinil on the pharmacokinetics of zamicastat under fed conditions and the safety of the drugs, presented at the 117th International Conference of the American Thoracic Society.
- 23 Dec 2020 New trial record